Progyny, Inc. $PGNY Shares Sold by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans trimmed its position in shares of Progyny, Inc. (NASDAQ:PGNY) by 55.9% in the third quarter, HoldingsChannel.com reports. The fund owned 2,158,310 shares of the company’s stock after selling 2,730,870 shares during the period. Thrivent Financial for Lutherans’ holdings in Progyny were worth $46,447,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. California State Teachers Retirement System boosted its position in Progyny by 0.7% in the 2nd quarter. California State Teachers Retirement System now owns 70,421 shares of the company’s stock valued at $1,549,000 after buying an additional 457 shares during the period. Teza Capital Management LLC boosted its holdings in Progyny by 5.4% in the second quarter. Teza Capital Management LLC now owns 10,068 shares of the company’s stock valued at $221,000 after purchasing an additional 516 shares during the period. Oxford Asset Management LLP grew its stake in Progyny by 4.3% during the 2nd quarter. Oxford Asset Management LLP now owns 12,918 shares of the company’s stock worth $284,000 after purchasing an additional 531 shares in the last quarter. M&G PLC grew its stake in Progyny by 2.6% during the 2nd quarter. M&G PLC now owns 30,542 shares of the company’s stock worth $672,000 after purchasing an additional 764 shares in the last quarter. Finally, Walleye Capital LLC increased its holdings in Progyny by 6.9% during the 2nd quarter. Walleye Capital LLC now owns 12,080 shares of the company’s stock worth $266,000 after purchasing an additional 780 shares during the period. 94.93% of the stock is currently owned by hedge funds and other institutional investors.

Progyny Stock Up 1.4%

PGNY opened at $24.20 on Tuesday. The firm has a market cap of $2.09 billion, a price-to-earnings ratio of 38.41, a price-to-earnings-growth ratio of 1.51 and a beta of 0.96. Progyny, Inc. has a 52 week low of $17.98 and a 52 week high of $28.75. The business’s 50 day moving average is $25.61 and its two-hundred day moving average is $23.34.

Progyny (NASDAQ:PGNY) last announced its earnings results on Thursday, November 6th. The company reported $0.45 EPS for the quarter, beating analysts’ consensus estimates of $0.39 by $0.06. The business had revenue of $313.35 million for the quarter, compared to analysts’ expectations of $299.23 million. Progyny had a net margin of 4.46% and a return on equity of 10.71%. The company’s quarterly revenue was up 9.3% on a year-over-year basis. During the same period in the previous year, the company posted $0.11 EPS. Progyny has set its FY 2025 guidance at 1.790-1.820 EPS and its Q4 2025 guidance at 0.370-0.400 EPS. Equities analysts expect that Progyny, Inc. will post 0.6 EPS for the current fiscal year.

Insider Activity

In related news, CFO Mark S. Livingston sold 21,303 shares of the firm’s stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $25.50, for a total transaction of $543,226.50. Following the transaction, the chief financial officer owned 48,358 shares of the company’s stock, valued at $1,233,129. This trade represents a 30.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Peter Anevski acquired 79,500 shares of Progyny stock in a transaction on Thursday, November 13th. The shares were bought at an average cost of $24.29 per share, with a total value of $1,931,055.00. Following the completion of the purchase, the chief executive officer owned 680,251 shares in the company, valued at $16,523,296.79. The trade was a 13.23% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have sold 22,046 shares of company stock valued at $561,691 in the last quarter. Insiders own 9.40% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the company. Citigroup raised Progyny to an “outperform” rating in a research report on Tuesday, January 20th. Citizens Jmp upgraded shares of Progyny from a “market perform” rating to an “outperform” rating and set a $30.00 price target for the company in a report on Tuesday, January 20th. Zacks Research lowered shares of Progyny from a “strong-buy” rating to a “hold” rating in a report on Friday. BTIG Research reiterated a “buy” rating on shares of Progyny in a research note on Wednesday, January 21st. Finally, KeyCorp raised their price target on Progyny from $30.00 to $32.00 and gave the company an “overweight” rating in a research note on Thursday, January 8th. Nine analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $29.36.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.